PALI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of -49.65%. Palisade Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Palisade Bio has a consensus price target of $18.00, signalling upside risk potential of 2587.37%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.27%. Given that Palisade Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palisade Bio is more attractive than NovaBay Pharmaceuticals.

Palisade Bio has a beta of 1.496, which suggesting that the stock is 49.608% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Palisade Bio's net income of -$3.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Palisade Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Palisade Bio's net margin of -2357.27%. Palisade Bio's return on equity of -- beat Palatin Technologies's return on equity of --.

Palisade Bio has a consensus price target of $18.00, signalling upside risk potential of 2587.37%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1326.24%. Given that Palisade Bio has higher upside potential than Palatin Technologies, analysts believe Palisade Bio is more attractive than Palatin Technologies.

Palisade Bio has a beta of 1.496, which suggesting that the stock is 49.608% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Palisade Bio's net income of -$3.3M is lower than Palatin Technologies's net income of -$2.4M. Notably, Palisade Bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of 24.22%. Palisade Bio's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Palisade Bio has a consensus price target of $18.00, signalling upside risk potential of 2587.37%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $916.63 which suggests that it could grow by 48.56%. Given that Palisade Bio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Palisade Bio is more attractive than Regeneron Pharmaceuticals.

Palisade Bio has a beta of 1.496, which suggesting that the stock is 49.608% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Palisade Bio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Palisade Bio's net income of -$3.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Palisade Bio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 5.00x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -- compared to Palisade Bio's net margin of -489.18%. Palisade Bio's return on equity of -- beat Sutro Biopharma's return on equity of -204.67%.

Palisade Bio has a consensus price target of $18.00, signalling upside risk potential of 2587.37%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 475.94%. Given that Palisade Bio has higher upside potential than Sutro Biopharma, analysts believe Palisade Bio is more attractive than Sutro Biopharma.

Palisade Bio has a beta of 1.496, which suggesting that the stock is 49.608% more volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.657%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Sutro Biopharma quarterly revenues of $14.8M. Palisade Bio's net income of -$3.3M is higher than Sutro Biopharma's net income of -$72.4M. Notably, Palisade Bio's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.74x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.